Keyword: Dupixent

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Dupixent is on track to deliver about €2 billion in annual sales, but Sanofi execs say they're still in early stages of the launch.

As Pfizer advances a phase 3 rival to Regeneron and Sanofi's Dupixent, one analyst says it'll struggle to steal share because of side effects.

GlaxoSmithKline's Nucala has been on the prowl for a leg up in severe asthma. Could new real-world data work some magic for the drug?

Regeneron has lost its edge in antibody development, so its growth potential may be limited, Analysts at SVBLeerink argue in a new report.

Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can they stop the drugmakers from adding another indication?

Regeneron is humming along on the strength Eylea and Dupixent. Now, it’s expanding its production to keep up with that growth.

Regeneron is working to keep Eylea on top of the wet AMD market. Could a new prefilled syringe application give the drug a leg up?

More than a decade in, Sanofi and Regeneron's antibody partnership has spawned several drugs, but it took Dupixent to fuel its first profit.

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.